AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Dapagliflozin Attenuates Fibroproliferative Remodeling Through Flow-Mediated Endothelial-Protective AMPKα-KLF2 Signaling
By Gaal J, Diaz-Gil D, Im GB et al.
Background: Many congenital heart defects (CHD), including hypoplastic left heart syndrome (HLHS), are characterized by disturbed intracardiac flow, which contributes to the development of endocardial fibroelastosis (EFE), a fibroproliferative endocardial disease associated with diastolic dysfunction. This disturbed flow promotes the endothelial-to-mesenchymal transition (EndMT) of endocardial endothelial cells (EECs) into fibroblasts, whereas physiological flow activates endothelial-protective AMPKα-KLF2 signaling in the vasculature. Dapagliflozin (DAPA), a selective SGLT2-inhibitor, has been shown to have cardioprotective effects. However, its underlying mechanisms remain incompletely understood. Hypothesis: We hypothesized that DAPA exerts its cardioprotective benefits by promoting a pro-endothelial phenotype through upregulation of AMPK-KLF2 signaling. Methods: We included six patients with HLHS/EFE, diastolic dysfunction, and echocardiographic evidence of in vivo flow disturbances. EECs were isolated from EFE tissue resected during ventricular rehabilitation surgery and cultured. Cells were treated with 0.5 μM DAPA (clinically relevant plasma concentration) or vehicle. RT-qPCR and flow cytometry were used to assess activation of the AMPK-KLF2 pathway and EndMT-related targets at the transcriptional and protein levels. Additionally, EdU incorporation assays quantified fibroproliferation. Results: At the transcriptional level, DAPA treatment significantly upregulated the endothelial-protective transcription factor KLF2 and its direct downstream target NOS3 by 2.74-fold (P=0.031) and 1.96-fold (P=0.04), respectively (Figure 1). In parallel, the pro-fibrotic, EndMT-associated transcription factor SMAD2 and the mesenchymal marker vimentin were significantly downregulated to 0.83-fold (P=0.006) and 0.81-fold (P=0.003) of untreated control levels, respectively (Figure 1). At the protein level, flow cytometric analysis demonstrated significantly increased expression of flow-responsive phospho-AMPKα and KLF2 in DAPA-treated EECs compared with untreated controls (37.5±12.3% vs. 20.6±8.3%, P=0.008; and 35.8±15.5% vs. 21.1±6.4%, P=0.048, respectively), consistent with activation of the AMPK-KLF2 signaling axis (Figure 2). Functionally, DAPA treatment also significantly attenuated fibroproliferation in EECs, reducing the proportion of proliferating cells from 15±8.5% in untreated controls to 6.6±6% (P=0.02), suggesting a potential anti-remodeling effect. Conclusion: Our findings suggest that DAPA may represent a promising therapeutic strategy to mitigate diastolic dysfunction in CHD by inhibiting EndMT and attenuating fibroproliferative processes through restoring physiological flow-responsive AMPK-KLF2 signaling in the diseased endocardium.